A pilot study of extremely low-frequency magnetic fields in advanced non-small cell lung cancer: Effects on survival and palliation of general symptoms

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 1130-1134

  Sun, Chengtao ^a   Yu, Huiming ^a   Wang, Xingwen ^a   Han, Junqing ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Extremely low frequency magnetic fields; General symptoms; Non small cell lung cancer; Survival analysis; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADULT; AGED; APPETITE DISORDER; ARTICLE; BLOOD ANALYSIS; CANCER LOCALIZATION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DYSPNEA; ELECTROCARDIOGRAM; ELECTROMAGNETIC FIELD; EVALUATION AND FOLLOW UP; EXTREMELY LOW FREQUENCY MAGNETIC FIELD; FEMALE; HUMAN; INCREASED APPETITE; INSOMNIA; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAGNETIC FIELD; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTPATIENT CARE; PHYSICAL CAPACITY; PHYSICAL EXAMINATION; PILOT STUDY; PLEURA EFFUSION; SURVIVAL RATE; TELECONSULTATION;

EID: 84866117554     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.867     Document Type: Article

References (22)

1. Huang L, Dong L, Chen Y, Qi H and Xiao D: Effects of sinusoidal magnetic field observed on cell proliferation, ion concentration, and osmolarity in two human cancer cell lines. Electromagn Biol Med 25: 113-126, 2006.
2. Tofani S, Barone D, Berardelli M, Berno E, Cintorino M, FogliaL, Ossola P, Ronchetto F, Toso E and Eandi M: Static and ELF magnetic fields enhance the in vivo anti-tumor efficacy of cis-platin against lewis lung carcinoma, but not of cyclophosphamide against B16 melanotic melanoma. Pharmacol Res 48: 83-90, 2003.
3. Novikov VV, Novikov GV and Fesenko EE: Effect of weak combined static and extremely low-frequency alternating magnetic fields on tumor growth in mice inoculated with the Ehrlich ascites carcinoma. Bioelectromagnetics 30: 343-351, 2009.
4. Zhang X, Zhang H, Zheng C, Li C, Zhang X and Xiong W: Extremely low frequency (ELF) pulsed-gradient magnetic fields inhibit malignant tumour growth at different biological levels. Cell Biol Int 26: 599-603, 2002.
5. Ronchetto F, Barone D, Cintorino M, Berardelli M, LissoloS, Orlassino R, Ossola P and Tofani S: Extremely low frequency-modulated static magnetic fields to treat cancer: A pilot study on patients with advanced neoplasm to assess safety and acute toxicity. Bioelectromagnetics 25: 563-571, 2004.
6. Elson E: I. The little explored efficacy of magnetic fields in cancer treatment and postulation of the mechanism of action. Electromagn Biol Med 28: 275-282, 2009.
7. Ruiz-Gómez MJ and Martínez-Morillo M: Electromagnetic fields and the induction of DNA strand breaks. Electromagn Biol Med 28: 201-214, 2009.
8. Lee HJ, Gimm YM, Choi HD, Kim N, Kim SH and Lee YS: Chronic exposure of Sprague-Dawley rats to 20 kHz triangular magnetic fields. Int J Radiat Biol 86: 384-389, 2010.
9. Wang T, Nie Y, Zhao S, Han Y, Du Y and Hou Y: Involvement of midkine expression in the inhibitory effects of low-frequency magnetic fields on cancer cells. Bioelectromagnetics 32: 443-452, 2011.
10. de Seze R, Tuffet S, Moreau JM and Veyret B: Effects of 100 mT time varying magnetic fields on the growth of tumors in mice. Bioelectromagnetics 21: 107-111, 2000.
11. Tofani S, Barone D, Cintorino M, de Santi MM, Ferrara A, Orlassino R, Ossola P, Peroglio F, Rolfo K and Ronchetto F: Static and ELF magnetic fields induce tumor growth inhibition and apoptosis. Bioelectromagnetics 22: 419-428, 2001.
12. Hisamitsu T, Narita K, Kasahara T, Seto A, Yu Y and AsanoK: Induction of apoptosis in human leukemic cells by magnetic fields. Jpn J Physiol 47: 307-310, 1997.
13. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, ZenK, Zhang C and Shen H: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28: 1721-1726, 2010.
14. Gao G, Chu H, Zhao L, Gui T, Xu Q and Shi J: A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 76: 380-386, 2012.
15. Novello S and Le Chevalier T: Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 17: 357-364, 2003.
16. Guo L, Bai SP, Zhao L and Wang XH: Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol: Sep 18, 2011 (E-pub ahead of print).
17. Adamsen L, Quist M, Midtgaard J, Andersen C, Møller T, Knutsen L, Tveterås A and Rorth M: The effect of a multidimensional exercise intervention on physical capacity, well-being and quality of life in cancer patients undergoing chemotherapy. Support Care Cancer 14: 116-127, 2006.
18. No authors listed: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909, 1995.
19. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, PaesmansM, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D and Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group: Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99: 847-857, 2007.
20. Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N and von Pawel J: Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 5: 369-375, 2010.
21. Qi WX, Shen Z and Yao Y: Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 69: 99-106, 2012.
22. Qi WX, Tang LN, He AN, Shen Z and Yao Y: Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 138: 745-751, 2012.